#USA #New York #Securities Fraud #Pomerantz Law Firm #Ventyx Biosciences

Pomerantz Law Firm Investigates Ventyx Biosciences, Inc.

Pomerantz LLP has initiated an investigation on behalf of investors of Ventyx Biosciences, Inc., known by its NASDAQ ticker symbol VTYX. This investigation centers on the activities of Ventyx and some of its key officers and directors regarding potential securities fraud and other illegal business practices. Investors seeking further information are encouraged to contact Daniella Peyton at Pomerantz LLP directly.

Recent Developments

On December 2, 2025, Ventyx published a press release that provided an update regarding its ongoing Phase 2 clinical trial for VTX2735, which is aimed at treating patients with recurrent pericarditis. The statement from the CEO indicated a revision to their projection for the release of topline data based on an interim analysis. The company's guidance now suggests that this data will be available in the first quarter of 2026. This adjustment was characterized as a strategic move, allowing the company to implement dose-ranging studies on a new formulation of the medication while also enabling its expansion into markets such as Canada, the EU, and the UK. The CEO expressed that this strategy could streamline timelines towards the Phase 3 trials.

However, the market reacted negatively to this announcement, leading to a notable decline in Ventyx's stock price. Following this news, the stock dropped by $1.44, representing a significant decrease of 15.35%, and closed at $7.94 per share on the same day. This dramatic decline in stock value is a key factor prompting the investigation into potential misconduct.

About Pomerantz LLP

Established in 1946, Pomerantz LLP has become a leading firm in corporate, securities, and antitrust class litigation. With offices located in prominent cities around the globe, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a notable history of advocating for investors affected by corporate misconduct and securities fraud. The firm was founded by Abraham L. Pomerantz, whose legacy as the dean of the class action bar remains influential today. Over the past 85 years, Pomerantz has successfully obtained numerous multimillion-dollar settlements and judgments on behalf of its clients.

The firm is committed to fighting vigorously for the rights of investors and holds a strong reputation for handling securities class actions efficiently and successfully. Investors who believe they have sustained losses related to their investment in Ventyx Biosciences are encouraged to reach out and learn more about their rights.

For more details, visit Pomerantz's website.

Conclusion

This investigation by Pomerantz LLP serves as a reminder for investors to stay informed about market movements and potential legal claims associated with their investments. As Ventyx Biosciences continues its operations, the unfolding of this case may hold significant implications for shareholders in the coming months.